Lanean...
Allergen immunotherapy phase II trials: Challenges in dose finding
Phase II studies on allergen immunotherapy (AIT) should define the dose with the best balance between efficacy and safety (“optimal dose”). Their key role is based on dose selection for subsequent pivotal studies (phase III, field studies). Since products for AIT differ in composition and unit defin...
Gorde:
| Argitaratua izan da: | Allergol Select |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dustri-Verlag Dr. Karl Feistle
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7066681/ https://ncbi.nlm.nih.gov/pubmed/32176223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/ALX02033E |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|